Electrolyte Disorders in Prediabetics and in Patients With Type 2 Diabetes Mellitus

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-05-31

Study Completion Date

2024-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to assess serum sodium \[Na+\], potassium \[K+\] magnesium \[Mg2+\], calcium \[Ca2+\], and chloride \[Cl-\] levels in patients who are prediabetic, diabetics and diabetic with complications (Diabetes mellitus type 2)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessment of Serum Magnesium Level with Diabetic Foot Ulceration in Type II Diabetes Associated with Diabetic Nephropathy Patients

NCT06754878

Diabetes Mellitus

NOT_YET_RECRUITING

Serum Magnesium Level in Type 2 Diabetes Mellitus

NCT06059833

Diabetes Mellitus

UNKNOWN

Comorbidities in Type 2 Diabetes Mellitus

NCT05874141

Type 2 Diabetes

RECRUITING NA

Thyroid Dysfunction in Patients With Type 2 Diabetes With Early Diabetic Nephropathy.

NCT03154398

Evaluation Thyroid Functions in Diabetic Patient

COMPLETED

Serum Endostatin Type 2 Diabetic Patients

NCT03404037

Diabetes Mellitus, Type 2 Coronary Artery Disease Coronary Arteriosclerosis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Diabetes mellitus is a chronic disease that imposes enormous socioeconomic burdens attributable to complications of various bodily systems. Diabetes affected 463 million people (9.3% of all people) in 2019 and will affect 700 million (10.9%) by 2045.

According to the International Diabetes Federation (IDF), the prevalence of diabetes mellitus among Egyptian adults is 15.2%, which may be an underestimation. Therefore, diabetes mellitus should be thoroughly explored in terms of its risk factors, prevention, treatment, and consequences. Moreover, the general population should be aware of and well informed about all aspects of diabetes.

Prediabetes is a precursor before the diagnosis of diabetes mellitus. Adults with prediabetes often may show no signs or symptoms of diabetes but will have blood glucose levels higher than normal. The normal blood glucose level is between 70 - 99 mg/dL. In patients with prediabetes, the blood glucose levels elevated between 110 - 125 mg/dL.

Once the patient is diagnosed as prediabetes, he should be checked for progression to type 2 diabetes every one to two years. So early detection of prediabetes and so lifestyle changes through improved nutrition and physical activity are the first line treatment for preventing the transition from prediabetes to diabetes which can be as high as 70%.

A normal HbA1C level is below 5.7%, a level of 5.7-6.4% indicates prediabetes, and a level of 6.5% or more indicates diabetes. Within the 5.7-6.4% prediabetes range, the higher HbA1C, the greater risk is for developing type 2 diabetes.

Serum electrolytes are important cofactors for multiple enzymes and play a pivotal role in many key biological and physiological processes, including glucose metabolism. The excess or deficiency of these electrolytes was found to be linked to deleterious metabolism status.

Diabetic patients frequently develop a constellation of electrolyte disorders. These disturbances are particularly common in decompensated diabetics, especially in the context of diabetic ketoacidosis or nonketotic hyperglycemic hyperosmolar syndrome.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Mellitus and Electrolyte Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1- Prediabetics

Prediabetics who will be diagnosed by:

Glycated hemoglobin (HbA1C) test 5.7 - 6.4% % on two separate tests

Fasting blood sugar test 110-125 mg/dL (6.1 - 6.9 mmol/L) on two separate tests.

Glucose tolerance test 140 - 179 mg/dL (7.8 - 9.9 mmol/L)

No interventions assigned to this group

2- Diabetic patients without complications

Patients with Type 2 diabetes who will be diagnosed by:

Glycated hemoglobin (HbA1C) test ≥ 6.5% on two separate tests

Fasting blood sugar test ≥ 126 mg/dL (7 mmol/L) on two separate tests

Glucose tolerance test ≥ 200 mg/dL (11.1 mmol/L) Random blood sugar test ≥ 200 mg/dL (11.1 mmol/L)

No interventions assigned to this group

3- Diabetic patients with complications

Diabetic patients with complications (nephropathy, neuropathy, cardiovascular, retinopathy, metabolic disorders, diabetic ketoacidosis)

No interventions assigned to this group

4- Controls

apparently normal subjects who have matched age and sex with patients groups

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with prediabetes who will be diagnosed by:

* Glycated hemoglobin (HbA1C) test (6.1 - 6.4%) on two separate tests
* Fasting blood sugar test 110-125 mg/dL (5.6 - 6.9 mmol/L) on two separate tests.
* Glucose tolerance test 140 - 179 mg/dL (7.8 - 9.9 mmol/L)
* Patients with Type 2 diabetes who will be diagnosed by:

* Glycated hemoglobin (HbA1C) test ≥ 6.5% on two separate tests
* Fasting blood sugar test ≥ 126 mg/dL (7 mmol/L) on two separate tests
* Glucose tolerance test ≥ 200 mg/dL (11.1 mmol/L)
* Random blood sugar test ≥ 200 mg/dL (11.1 mmol/L)
* Patients with diabetic complications (nephropathy, neuropathy, cardiovascular, retinopathy, metabolic disorders, diabetic ketoacidosis)